Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$26,691 | -$26,874 | -$48,279 | -$47,472 |
| Dep. & Amort. | $160 | $160 | $262 | $317 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $4,828 | $6,286 | $6,486 | $31,363 |
| Change in WC | -$1,170 | -$8,328 | $1,754 | -$7,076 |
| Other Non-Cash | -$4,090 | -$5,952 | $7,141 | -$16,834 |
| Operating Cash Flow | -$26,963 | -$34,708 | -$32,636 | -$39,702 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | $0 |
| Net Acquisitions | $0 | $564 | $5 | $0 |
| Inv. Purchases | -$49,534 | -$40,186 | -$19,530 | -$39,217 |
| Inv. Sales/Matur. | $77,855 | $70,000 | $60,000 | $71,500 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $28,321 | $30,378 | $40,475 | $32,283 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $115 | $0 | $189 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $115 | $0 | $189 | $0 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $1,473 | -$4,330 | $8,028 | -$7,419 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $40,226 | $44,556 | $36,528 | $43,947 |
| End Cash | $41,699 | $40,226 | $44,556 | $36,528 |
| Free Cash Flow | -$26,963 | -$34,708 | -$32,636 | -$39,702 |